Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split effective January 28, 2025 James PhillipsJanuary 24, 2025
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients James PhillipsJanuary 21, 2025
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025 James PhillipsJanuary 13, 2025
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds James PhillipsDecember 3, 2024
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply Chester ZygmontNovember 12, 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 James PhillipsNovember 8, 2024
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 James PhillipsSeptember 24, 2024
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds James PhillipsAugust 21, 2024
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met The Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity James PhillipsJune 24, 2024
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini James PhillipsJune 13, 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 James PhillipsMay 10, 2024
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) James PhillipsMarch 13, 2024
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference James PhillipsMarch 12, 2024
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini James PhillipsMarch 4, 2024
Revelation Biosciences Inc. Receives Invitation to give an Oral Presentation at The 29th International James PhillipsFebruary 13, 2024
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering James PhillipsFebruary 5, 2024
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering James PhillipsFebruary 1, 2024
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) James PhillipsJanuary 30, 2024
